Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Not yet recruiting 2Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Hematopoietic and Lymphatic System Neoplasm 1Breast Neoplasms 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43Specimen Handling 41pembrolizumab 40anlotinib 40sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 29Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 26lenvatinib 24apatinib 23Docetaxel 23Etoposide 22Biopsy 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × axatilimab × Clear all
NCT07015853 2026-04-20

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
34 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07349771 2026-04-16

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Mayo Clinic

Phase 2 Not yet recruiting
72 enrolled

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡